v3.26.3
Acquisitions
9 Months Ended
Sep. 30, 2026
Business Combination [Abstract]  
Acquisitions

4. Acquisitions

Mantle Therapeutics Inc.

Mantle is a company focused on developing multiple therapies for the treatment of Friedreich Ataxia with modalities in the clinical, pre-clinical, and discovery stages of research and development. On September 16, 2026, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Mantle, Magma Merger Sub Inc., a Delaware corporation and a wholly-owned subsidiary of the Company (“Merger Sub”), and Shareholder Representative Services LLC, a Colorado limited liability company, solely in its capacity as representative, agent and attorney in fact of the sellers. Pursuant to the Merger Agreement, Merger Sub merged with and into Mantle (the “Merger”) upon the closing of the Merger on September 29, 2026, with Mantle continuing as the surviving corporation and wholly owned subsidiary of Lexeo. Upon closing of the Merger, the Company acquired 100% of the outstanding stock of Mantle for total initial consideration paid to the sellers of approximately $7.5 million including (i) approximately $5.0 million of cash, (ii) a fair value of approximately $2.2 million for 632,907 shares of the Company's common stock issued at a closing price of $3.42 per share on September 29, 2026, (iii) approximately $0.3 million of estimated net liabilities assumed, and (iv) approximately $10,000 of estimated final cash consideration receivable. Such estimated amounts of liabilities assumed and final cash consideration receivable as of September 30, 2026 are subject to final net working capital adjustments under the terms of the Merger Agreement that will conclude during the three months ending December 31, 2026.

Additionally, up to an aggregate $30.6 million is payable upon the potential achievement of certain development milestones, including up to an aggregate $10.0 million of cash payable, and also including $2.0 million of shares of the Company's common stock to be issued (the "Equity-based Contingent Consideration"), to the sellers, as well as including up to an aggregate $18.6 million of cash payable to a third party, Neurogenetics Consulting LLC ("Neurogenetics") (collectively, the "Mantle Development Milestones") (see Note 2). The total amount of up to $28.6 million payable in cash upon the potential achievement of the Mantle Development Milestones relates to certain development and regulatory-based milestones and zero relates to commercial-based milestones. As of September 30, 2026, any potential amounts due in cash upon the achievement of such cash-based Mantle Development Milestones were not deemed to be probable and no expenses or liabilities were recognized. The number of shares of the Company's common stock to be issued upon the potential achievement of the Equity-based Contingent Consideration is determined by the trailing 30-day volume-weighted average price per share of the Company's common stock as of the date of such milestone achievement. Further, an additional payment amount of $1.0 million is payable based on the potential achievement of a certain business event within 60 days of the announcement of the acquisition on September 22, 2026 (the "Mantle Additional Payment Amount").

In addition to the amounts payable by the Company to the sellers of Mantle upon the potential achievement of the cash-based Mantle Development Milestones, as well as upon the potential achievement of the Mantle Additional Payment Amount, the Company is required to pay to Mantle's sellers most of any revenue earned under any potential out-licensing or partnership agreement entered into for one of the acquired IPR&D assets within one year of the acquisition closing date (the "Mantle Revenue Agreement"). Upon the potential achievement of the Mantle Revenue Agreement, $5.0 million of the amounts due in cash by the Company to the sellers of Mantle upon the potential achievement of certain cash-based Mantle Development Milestones are no longer payable. As of September 30, 2026, any potential amounts due under the terms of the Mantle Revenue Agreement were not deemed to be probable and no expenses or liabilities were recognized.

In August 2024, Mantle entered into a research and development agreement with Neurogenetics to develop therapies for Friedreich Ataxia utilizing novel, small, chemical molecule drugs (the "Neurogenetics Agreement"). Under the terms of the Neurogenetics Agreement, in addition to the amounts payable in cash by Mantle to Neurogenetics upon the potential achievement of the cash-based Mantle Development Milestones, Mantle is required to pay to Neurogenetics low-single digit royalties based on gross sales. The Neurogenetics Agreement may be terminated by mutual written consent of both parties, and may be terminated by Mantle upon 10 days' prior written notice to Neurogenetics.

Upon the closing of the acquisition, the Company concurrently entered into an employment agreement with a former employee of Mantle as well as a part-time, one-year consulting agreement with a former employee of Mantle. The Company accounted for the acquisition of Mantle as an asset acquisition pursuant to ASC Topic 805, Business Combinations.

The $2.0 million of shares of the Company's common stock to be issued upon the potential future achievement of the Equity-based Contingent Consideration was accounted for as a liability in accordance with the provisions of ASC Topic 480, Distinguishing Liabilities from Equity, and the potential future achievement of the $1.0 million Mantle Additional Payment Amount payable to the sellers of Mantle was accounted for as a derivative instrument and a liability in accordance with ASC Topic 815, Derivatives and Hedging (collectively, the "Contingent Consideration Liabilities"), which were charged to research and development expense and will be subsequently measured at fair value with changes in fair value recognized in earnings (see Note 3).

The Company acquired four IPR&D assets from Mantle related to Friedreich Ataxia programs that are in the clinical, pre-clinical, and discovery stages of research and development. The total fair value of the IPR&D acquired was approximately $9.9 million and was charged to research and development expense as it had no alternative future use at the time of the acquisition, including approximately $1.1 million of estimated third party transaction costs directly associated with the acquisition of Mantle. The initial consideration recognized and the fair value of the assets acquired are as follows:

Initial cash consideration paid

 

$

5,009

 

 

Final cash consideration payable (receivable), estimated

 

 

(10

)

 

Net liabilities assumed, estimated

 

 

321

 

 

Fair value of shares of the Company's common stock issued

 

 

2,165

 

 

Fair value of Contingent Consideration Liabilities

 

 

1,267

 

 

Transaction costs, estimated

 

 

1,122

 

 

Consideration paid

 

$

9,874

 

 

Assets acquired:

 

 

 

 

Acquired in-process research and development

 

$

9,874

 

 

Total assets acquired

 

$

9,874